质子抑制剂和尿病的风险:孟德尔的随机化研究
Jiawei Guo1, Xinyu Chen, Yongqi Dou
1Department of Urology, Yongchuan Hospital of Chongqing Medical University, Chongqing, PR China.
质子抑制剂 (PPI) 可能会因果性地增加尿病 (UL) 的风险,而Rabeprazole与更高的发病率有关. 埃索梅普拉显示出对UL的潜在保护作用,这表明它可能是高风险患者的更安全选择.
科学领域:
- 药物基因组学 药物基因组学
- 胃肠病学 胃肠病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 观察性研究将质子抑制剂 (PPI) 与尿病 (UL) 风险的增加联系起来.
- PPI使用和UL之间的因果关系仍然不确定.
- 遗传关联研究提供了调查因果关系的工具.
研究的目的:
- 使用双样本的门德尔随机化方法,研究PPI和尿病 (UL) 之间的因果关系.
- 评估常见的PPI (包括拉贝普拉和埃索梅普拉) 对UL风险的特定因果影响.
- 提供基于证据的建议,为患有尿病风险的患者选择PPI.
主要方法:
- 使用了2个样本的孟德尔随机化分析.
- 使用的全基因组关联研究 (GWAS) 数据用于PPI (奥梅普拉,埃索梅普拉,兰索普拉,拉贝普拉) 和UL.
- 应用随机效应逆变量权衡作为主要分析方法,使用灵敏度分析和独立的UL数据集进行验证.
主要成果:
- 拉贝普拉的使用与5%的尿病 (UL) 发病率增加有关 (OR=1.053,95% CI:1.005-1.103).
- 埃索梅普拉与UL风险呈负相关性 (OR=0.914,95% CI:0.841-0.993).
- 敏感性分析证实了这些发现的可靠性.
结论:
- 这项研究表明,使用质子抑制剂 (PPI) 和尿病 (UL) 之间存在因果关系.
- 埃索梅普拉可能是拉贝普拉的最佳替代品,用于抑制酸性,特别是在易患结石的个体中.
- 这些发现支持基于尿病风险因素的个性化PPI选择.
更多相关视频
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Urinary Tract Calculi III: Medical Management
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
